HRP20160802T1 - Čvrsti farmaceutski pripravci koji sadrže derivate biopterina i upotreba takvih pripravaka - Google Patents

Čvrsti farmaceutski pripravci koji sadrže derivate biopterina i upotreba takvih pripravaka Download PDF

Info

Publication number
HRP20160802T1
HRP20160802T1 HRP20160802TT HRP20160802T HRP20160802T1 HR P20160802 T1 HRP20160802 T1 HR P20160802T1 HR P20160802T T HRP20160802T T HR P20160802TT HR P20160802 T HRP20160802 T HR P20160802T HR P20160802 T1 HRP20160802 T1 HR P20160802T1
Authority
HR
Croatia
Prior art keywords
pharmaceutical preparation
compound
image
formula
phosphate
Prior art date
Application number
HRP20160802TT
Other languages
English (en)
Croatian (hr)
Inventor
Frank Tegtmeier
Reinhard Schinzel
Peter Scheurer
Original Assignee
Vasopharm Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vasopharm Gmbh filed Critical Vasopharm Gmbh
Publication of HRP20160802T1 publication Critical patent/HRP20160802T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
HRP20160802TT 2014-03-31 2016-07-06 Čvrsti farmaceutski pripravci koji sadrže derivate biopterina i upotreba takvih pripravaka HRP20160802T1 (hr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP14162727.3A EP2926805B1 (en) 2014-03-31 2014-03-31 Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions

Publications (1)

Publication Number Publication Date
HRP20160802T1 true HRP20160802T1 (hr) 2016-08-12

Family

ID=50389975

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20160802TT HRP20160802T1 (hr) 2014-03-31 2016-07-06 Čvrsti farmaceutski pripravci koji sadrže derivate biopterina i upotreba takvih pripravaka

Country Status (28)

Country Link
US (7) US9895372B2 (enExample)
EP (2) EP2926805B1 (enExample)
JP (3) JP6552515B2 (enExample)
KR (1) KR102374500B1 (enExample)
CN (2) CN113521017A (enExample)
AU (2) AU2015239736B2 (enExample)
CA (1) CA2938267C (enExample)
CL (1) CL2016002463A1 (enExample)
CY (1) CY1117881T1 (enExample)
DK (1) DK2926805T3 (enExample)
ES (1) ES2586945T3 (enExample)
HR (1) HRP20160802T1 (enExample)
HU (1) HUE030221T2 (enExample)
IL (1) IL248090B (enExample)
MX (1) MX377919B (enExample)
MY (1) MY180844A (enExample)
PE (1) PE20161253A1 (enExample)
PH (1) PH12016501519B1 (enExample)
PL (1) PL2926805T3 (enExample)
PT (1) PT2926805T (enExample)
RS (1) RS54973B1 (enExample)
RU (1) RU2694368C2 (enExample)
SA (1) SA516371933B1 (enExample)
SG (1) SG11201606151SA (enExample)
SI (1) SI2926805T1 (enExample)
SM (1) SMT201600246B (enExample)
WO (1) WO2015150294A1 (enExample)
ZA (1) ZA201605271B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9499532B2 (en) 2014-02-07 2016-11-22 eXIthera Pharmaceuticals Inc. Therapeutic compounds and compositions
ES2586945T3 (es) * 2014-03-31 2016-10-19 Vasopharm Gmbh Composiciones farmacéuticas sólidas que comprenden derivados de biopterina y usos de dichas composiciones
JP2016168783A (ja) * 2015-03-13 2016-09-23 株式会社東芝 記録装置、記録方法、及び記録媒体
US12171766B2 (en) 2021-12-03 2024-12-24 Verinos Operations Gmbh Methods of treating patients suffering from brain injury and methods of increasing the value of the extended Glasgow Outcome Scale of patients suffering from brain injury
MX2020002271A (es) * 2017-09-01 2020-10-05 Ptc Therapeutics Mp Inc Composiciones farmaceuticas que comprenden sepiapterina y sus usos de las mismas.
JP6565103B2 (ja) * 2017-09-06 2019-08-28 株式会社昭和冷凍プラント 香気成分含有水溶液を含む液状製品の製造方法
IL291565B1 (en) * 2019-09-25 2026-04-01 Ptc Therapeutics Inc Method for treating phenylalanine irregularity
AU2021476139A1 (en) 2021-12-03 2024-05-09 Tibeay Biosciences B.V. Methods of treating patients suffering from brain injury and methods of increasing the value of the extended glasgow outcome scale of patients suffering from brain injury
TW202406555A (zh) 2022-05-06 2024-02-16 德商veriNOS運營有限公司 治療患有與增加的麩胺酸水平相關的疾病狀況或病症的患者的方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5922713A (en) * 1997-06-26 1999-07-13 Werner; Ernst Inhibition of nitric oxide synthase
ATE201412T1 (de) 1997-10-06 2001-06-15 Ernst Werner Pteridinderivate als no synthase-hemmer
US6803046B2 (en) * 2002-08-16 2004-10-12 Bracco International B.V. Sincalide formulations
WO2005037286A1 (en) * 2003-03-25 2005-04-28 Vasopharm Biotech Gmbh Use of pteridine derivatives for the treatment of increased intracranial pressure and secondary ischemia
CA2545968C (en) * 2003-11-17 2010-03-09 Merck Eprova Ag Crystalline forms of (6r)-l-erythro-tetrahydrobiopterin dihydrochloride
US20080207624A1 (en) * 2004-05-11 2008-08-28 Osamu Sugita Therapeutic Agent for Bh4-Responsive Hyperphenylalaninemia
SE0401826D0 (sv) 2004-07-09 2004-07-09 Trimble Ab Method of preparing a winding for an n-phase motor
CN101132776A (zh) * 2004-11-17 2008-02-27 生物马林药物股份有限公司 稳定的四氢生物喋呤片剂制剂
EP1669355A1 (en) * 2004-12-02 2006-06-14 Vasopharm Biotech GmbH Aminotetrahydropteridines and processes for manufacture thereof
KR20160065998A (ko) * 2007-04-11 2016-06-09 바이오마린 파머수티컬 인크. 테트라하이드로바이오프테린 투여 방법, 관련 조성물 및 측정 방법
EP2140731A2 (de) 2007-04-24 2010-01-06 Osram Gesellschaft mit Beschränkter Haftung Schaltungsanordnung zur zündung und zum betrieb einer entladungslampe
WO2010017570A2 (de) 2008-08-12 2010-02-18 Orpha Swiss Gmbh Pharmazeutische darreichungsform enthaltend tetrahydrobiopterin
CA2828685C (en) * 2011-03-01 2018-05-29 Rubicon Research Private Limited Stable compositions of tetrahydrobiopterin
WO2013033194A1 (en) * 2011-08-30 2013-03-07 Fresenius Kabi Usa, Llc Levothyroxine formulations
ES2586945T3 (es) * 2014-03-31 2016-10-19 Vasopharm Gmbh Composiciones farmacéuticas sólidas que comprenden derivados de biopterina y usos de dichas composiciones

Also Published As

Publication number Publication date
IL248090B (en) 2019-10-31
CY1117881T1 (el) 2018-03-07
MX377919B (es) 2025-03-10
US12458644B2 (en) 2025-11-04
PH12016501519A1 (en) 2017-02-06
MY180844A (en) 2020-12-10
US11717522B2 (en) 2023-08-08
US20260048056A1 (en) 2026-02-19
JP7178731B2 (ja) 2022-11-28
US20170296543A1 (en) 2017-10-19
JP2021105062A (ja) 2021-07-26
IL248090A0 (en) 2016-11-30
HK1213195A1 (en) 2016-06-30
EP2926805A1 (en) 2015-10-07
AU2015239736B2 (en) 2020-03-26
SG11201606151SA (en) 2016-08-30
JP6552515B2 (ja) 2019-07-31
US20220031703A9 (en) 2022-02-03
US10016431B2 (en) 2018-07-10
WO2015150294A1 (en) 2015-10-08
JP2019194227A (ja) 2019-11-07
RU2694368C2 (ru) 2019-07-12
PL2926805T3 (pl) 2016-12-30
CN106572976A (zh) 2017-04-19
JP6879582B2 (ja) 2021-06-02
SMT201600246B (it) 2016-08-31
US20230355630A1 (en) 2023-11-09
US9895372B2 (en) 2018-02-20
ES2586945T3 (es) 2016-10-19
AU2015239736A1 (en) 2016-08-11
SI2926805T1 (sl) 2016-09-30
RS54973B1 (sr) 2016-11-30
US20210137927A1 (en) 2021-05-13
US10493075B2 (en) 2019-12-03
KR102374500B1 (ko) 2022-03-15
US20170112836A1 (en) 2017-04-27
PT2926805T (pt) 2016-07-15
DK2926805T3 (en) 2016-07-25
CA2938267C (en) 2023-05-09
JP2017509623A (ja) 2017-04-06
CN113521017A (zh) 2021-10-22
CA2938267A1 (en) 2015-10-08
PE20161253A1 (es) 2016-11-13
US10925877B2 (en) 2021-02-23
RU2016141449A3 (enExample) 2018-12-14
BR112016020101A2 (enExample) 2017-07-15
HUE030221T2 (en) 2017-04-28
NZ722455A (en) 2022-03-25
AU2020203880B2 (en) 2022-03-31
CL2016002463A1 (es) 2017-01-27
RU2016141449A (ru) 2018-05-07
MX2016012784A (es) 2017-04-25
AU2020203880A1 (en) 2020-07-02
SA516371933B1 (ar) 2019-04-14
US20180289714A1 (en) 2018-10-11
BR112016020101A8 (pt) 2021-06-29
US20200046710A1 (en) 2020-02-13
KR20160138406A (ko) 2016-12-05
ZA201605271B (en) 2017-08-30
EP2926805B1 (en) 2016-05-18
EP3125864A1 (en) 2017-02-08
PH12016501519B1 (en) 2017-02-06

Similar Documents

Publication Publication Date Title
HRP20180007T1 (hr) Formulacija koja sadrži gemcitabin-predlijek
SG10201804024VA (en) Formulations of azaindole compounds
EA201291348A1 (ru) Активаторы растворимой гуанилатциклазы
RU2017134002A (ru) Стабильные композиции тетрагидробиоптерина
JP2017509623A5 (enExample)
HRP20191285T1 (hr) Predlijekovi karbidopa i l-dopa te njihova uporaba za liječenje parkinsonove bolesti
BR112017010551A2 (pt) composto, métodos para ativação de guanilato ciclase solúvel, para tratamento de uma ou mais condições selecionadas a partir de uma doença em um paciente e para tratamento de uma doença ou condição, composição farmacêutica, uso de um composto, e, medicamento.
HRP20211278T1 (hr) Supstituirani derivati indolina kao inhibitori replikacije denga virusa
HRP20140011T1 (hr) Derivati oksazina i njihova uporaba u lijeäśenju neuroloških poremeä†aja
HRP20200196T1 (hr) Fiziološki balansirane injektabilne formulacije fosnetupitanta
JP2016534142A5 (enExample)
RU2016141449A (ru) Твердые фармацевтические композиции, содержащие производные биоптерина, и способы применения таких композиций
BR112015020823A8 (pt) 1-hidróxi-benzooxaboróis como agentes antiparasíticos, seus usos, e formulação".
AR105203A1 (es) Formulación oral sólida que contiene irinotecán y método de preparación de la misma
EA201691490A1 (ru) Фармацевтическая композиция, содержащая бринзоламид
HRP20240166T1 (hr) Postupak liječenja prader-willijevog sindroma
ME02405B (me) Spojevi pirazola као inhibitori sglt1
MX2016001422A (es) Composicion farmaceutica de fingolimod.
HRP20210010T1 (hr) Injekcijske farmaceutske formulacije lefamulina
JP2015526463A5 (enExample)
RU2016121401A (ru) Устойчивые при хранении лиофилизованные составы трипептидов
HRP20211761T1 (hr) Dvokomponentna kompozicija koja sadrži acetilsalicilnu kiselinu
HRP20210418T1 (hr) Liječenje s syd985 pacijenata s rakom koji ne reagira na t-dm1
RU2015145451A (ru) Препараты для местного применения, содержащие гиалуроновую кислоту, вербаскозид и глицерофосфоинозитол
HRP20201598T1 (hr) Pripravci